{
    "type": "ETF",
    "ucits": true,
    "replication_method": "physical",
    "leverage": false,
    "derivatives": false,
    "swaps": false,
    "inverse": false,
    "complex_factors": [],
    "classification": "non-complex",
    "supporting_data": "The L&G Healthcare Technology & Innovation UCITS ETF is a UCITS-compliant ETF domiciled in Ireland, tracking the ROBO Global\u00ae Healthcare Technology and Innovation Index TR. The fund primarily uses physical full replication of the underlying index constituents, investing directly in publicly traded healthcare technology companies worldwide. The KIID and PRIIPs KID documents confirm that while the fund may use financial derivative instruments (FDIs), these are only for efficient portfolio management or to invest in technology companies with similar risk profiles, not as an inherent part of the investment strategy. There is no mention of synthetic replication, swap agreements, or counterparty risk related to derivatives. The fact sheet explicitly states the replication method as physical full replication. There is no leverage, inverse exposure, or capital protection features. The risk rating is high (7/7) due to the nature of the underlying investments (small and mid-cap technology companies with volatile prices), but this does not imply complexity under MiFID II. Costs are straightforward with a single ongoing charge (TER) of 0.49%, no performance fees, and no complex fee structures. The index tracked is transparent and based on liquid, publicly traded equities, with no complex structured products or contingent bonds involved. No references to roll costs, contango, or backwardation effects are present. The PRIIPs KID does not carry any comprehension warnings or complexity flags. Therefore, the fund does not meet the MiFID II criteria for classification as a complex financial instrument."
}